Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Triple Negative Breast Neoplasms × efavirenz × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 50 Carboplatin 28 Paclitaxel 19 Cyclophosphamide 16 sacituzumab govitecan 15 Capecitabine 13 130-nm albumin-bound paclitaxel 13 Specimen Handling 11 Magnetic Resonance Spectroscopy 9 Drug Therapy 9 Docetaxel 9 Bevacizumab 9 toripalimab 8 olaparib 7 durvalumab 7 Doxorubicin 7 Biopsy 7 Epirubicin 6 Albumin-Bound Paclitaxel 6 camrelizumab 5 Taxes 5 Nivolumab 5 atezolizumab 4 Injections 4 Immune Checkpoint Inhibitors 4 tucatinib 3 tislelizumab 3 liposomal doxorubicin 3 fludarabine 3 eribulin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05076682 2025-12-03

Renaissance

Fudan University

Phase 2 Recruiting

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡